Presbia PLC (LENS) Receives Average Rating of “Strong Buy” from Brokerages

Presbia PLC (NASDAQ:LENS) has received an average broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a strong buy recommendation.

Brokers have set a 1 year consensus price objective of $8.50 for the company and are predicting that the company will post ($0.27) earnings per share for the current quarter, according to Zacks. Zacks has also given Presbia an industry rank of 161 out of 265 based on the ratings given to its competitors.

Several brokerages have commented on LENS. Zacks Investment Research upgraded shares of Presbia from a “sell” rating to a “hold” rating in a report on Tuesday, December 5th. HC Wainwright restated a “buy” rating and issued a $7.00 price objective on shares of Presbia in a report on Wednesday, December 20th.

An institutional investor recently raised its position in Presbia stock. FMR LLC boosted its stake in Presbia PLC (NASDAQ:LENS) by 0.5% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,568,278 shares of the medical instruments supplier’s stock after buying an additional 13,375 shares during the period. FMR LLC owned 15.15% of Presbia worth $5,856,000 at the end of the most recent reporting period. 16.05% of the stock is currently owned by institutional investors and hedge funds.

Shares of Presbia (NASDAQ:LENS) opened at $3.29 on Monday. The company has a quick ratio of 2.94, a current ratio of 3.02 and a debt-to-equity ratio of 0.07. Presbia has a 1-year low of $1.86 and a 1-year high of $7.14. The company has a market cap of $56.33, a PE ratio of -2.84 and a beta of -0.13.

TRADEMARK VIOLATION NOTICE: “Presbia PLC (LENS) Receives Average Rating of “Strong Buy” from Brokerages” was published by American Banking News and is owned by of American Banking News. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The original version of this report can be accessed at

Presbia Company Profile

Presbia PLC is an ophthalmic device company. The Company develops and markets an optical lens implant for treating presbyopia, the age-related loss of the ability to focus on near objects. The Company’s segment is the restoration of clear vision caused by presbyopia. The Company provides the refractive lens for patient surgeries and accessories for procedures performed exclusively outside the United States.

Get a free copy of the Zacks research report on Presbia (LENS)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Presbia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Presbia and related companies with's FREE daily email newsletter.

Leave a Reply